DBV Technologies
DBV Technologies' revenue rose 35.8% to $6 million in fiscal 2025. Its operating margin was −2,609.2%, up from −2,808.7% a year earlier. Free cash flow was −$122 million. The diluted share count rose 43.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What DBV Technologies does
DBV Technologies is a French drug developer working on treatments for food allergies in children. Its product, Viaskin, is a skin patch that carries a tiny dose of an allergen, such as peanut protein. The idea, called epicutaneous immunotherapy, is that cells in the skin carry the allergen to the immune system and slowly make the child less sensitive to it, without the allergen entering the bloodstream.
It has no approved products and no sales yet. Its main candidate, the Viaskin Peanut Patch, has been tested in twelve completed clinical trials. In its annual report the company said it planned to ask the US Food and Drug Administration for approval for children aged four to seven in the first half of 2026, and for toddlers aged one to three later in 2026 if a safety study succeeds. It also has earlier-stage work on a milk allergy patch. It names oral treatments for peanut allergy, such as Palforzia, and the antibody drug Xolair among other treatments.
DBV lost $146.9 million in 2025 and had $194.2 million in cash at the end of the year, before raising more from warrant exercises. Its headquarters are in Châtillon, France, and its main US office is in Warren, New Jersey. It had 125 full-time employees at the end of 2025.
Its biggest risks, as it describes them
- It depends almost entirely on its Viaskin patch, which may never win approval or sell well.
- Regulators in the United States or Europe may refuse or delay approval of its peanut patch.
- Continuing losses, and the need to raise more money that may not be available on good terms.
- Its reliance on outside manufacturers and suppliers, and the challenge of making patches at large scale.
- French law limits how easily it can issue new shares to raise capital.
Income statement
DBV Technologies lost money in fiscal 2025: a net loss of $147 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 77 | 209 | 141 | 32 | 194 |
| Debt incl. finance leases | 0 | — | — | — | — |
| Net debt (negative means net cash) | −77 | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 3.6x | 7.6x | 4.3x | 1.4x | 3.7x |
| Quick ratio | 3.6x | 7.6x | 4.3x | 1.4x | 3.7x |
Cash flow
Projections
Project DBV Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought DBV Technologies shares on the open market, and 2 insiders sold $15.5 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | Pharis MohideenChief Medical Officer | Sold | 464 | $2.70 | $1,253 | Form 4 |
| Jan 29, 2026 | Pharis MohideenChief Medical Officer | Sold | 534 | $4.86 | $2,595 | Form 4 |
| Dec 18, 2025 | Bpifrance EPICMember of 10% owner group | Sold | 1,292,103 | $4.19 | $5.4 million | Form 4 |
| Dec 17, 2025 | Bpifrance EPICMember of 10% owner group | Sold | 2,076,990 | $4.85 | $10.1 million | Form 4 |
| Nov 21, 2025 | Pharis MohideenChief Medical Officer | Sold | 1,624 | $2.77 | $4,498 | Form 4 |
| Nov 20, 2025 | Pharis MohideenChief Medical Officer | Sold | 6,496 | $2.88 | $18,708 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −286.1% | −2,646.8% | −2,123.8% |
| Altman Z'' | 0.74 | −24.08 | −2.64 |
| Accruals ratio | 71.0% | −7.6% | −17.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put DBV Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| DBV Technologies | FY25 | 35.8% | −2,609.2% | −2,159.6% | — | — | — | |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Cerenome | FY25 | −10.5% | −293.5% | −399.8% | — | — | — | Compare |
| Korro Bio | FY25 | 181.5% | −1,906.4% | −1,237.2% | — | — | — | Compare |
| X4 Pharmaceuticals | FY25 | 150.0% | −1,336.7% | −1,317.2% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | 15 | 11 | 6 | 5 | 16 | 4 | 6 |
| Revenue growth | — | — | — | — | −23.3% | −49.4% | −15.1% | 224.7% | −73.6% | 35.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | 115 | 102 | 70 | 76 | 60 | 89 | 117 |
| Operating income | — | — | — | −171 | −159 | −99 | −97 | −76 | −117 | −147 |
| Net income | — | — | — | −172 | −160 | −98 | 96 | 73 | −114 | −147 |
| Diluted EPS (US$) | — | — | — | −4.65 | −2.95 | −1.78 | −1.24 | −0.76 | −1.17 | −1.05 |
| Diluted shares (millions) | 24 | 24,757 | 28,925 | 37 | 54 | 55 | 77 | 95 | 97 | 140 |
| Cash flow | ||||||||||
| Cash from operations | — | — | — | −148 | −166 | −108 | −56 | −80 | −104 | −121 |
| Capital expenditure | — | — | — | 6 | 3 | 1 | 1 | 1 | 2 | 0 |
| Free cash flow | — | — | — | −154 | −168 | −109 | −56 | −80 | −107 | −122 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | 17 | −1 | 3 | 5 | 6 | 5 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | — | 141 | 193 | 196 | 77 | 209 | 141 | 32 | 194 |
| Debt incl. finance leases | — | — | 3 | 2 | 1 | 0 | — | — | — | — |
| Total assets | — | — | — | 272 | 272 | 147 | 246 | 183 | 66 | 234 |
| Total liabilities | — | — | — | 78 | 67 | 47 | 52 | 43 | 38 | 65 |
| Shareholders' equity | — | — | 139 | 193 | 206 | 99 | 194 | 140 | 27 | 169 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | −1,162.8% | −1,408.7% | −1,727.7% | −1,994.9% | −486.0% | −2,808.7% | −2,609.2% |
| Net margin | — | — | — | −1,169.5% | −1,415.0% | −1,713.5% | 1,987.5% | 462.3% | −2,744.3% | −2,607.3% |
| Free cash flow margin | — | — | — | −1,046.5% | −1,493.4% | −1,912.3% | −1,164.7% | −510.8% | −2,573.2% | −2,159.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | −1,516.7% | −1,961.6% | −1,179.9% | −286.1% | −2,646.8% | −2,123.8% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | −80.0% | −64.2% | 65.5% | 43.5% | −136.0% | −149.8% |
| Return on assets | — | — | — | — | −58.7% | −46.7% | 49.0% | 33.9% | −91.6% | −98.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |